NERV · Minerva Neurosciences, Inc
Minerva Neurosciences Inc (NERV)
What's happening
- NERV is down 1.24% today, trading at $2.39. — Live quote
- It's trading within 3% of its 52-week low ($2.24). (Finnhub fundamentals)
- Volume today (5,083) is well below its 3-month average of 227,080. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.17 actual vs. $-0.14 estimated (-22.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | $265.5M | $16.4M | $13.3M | $13.0M |
| P/E | — | -1.96 | 1.28 | 1.84 | 6.63 |
| Price/Book | — | -1.05 | -0.47 | -0.42 | -0.45 |
| ROE | — | 53.21% | -36.89% | -22.64% | -6.72% |
| ROA | — | -143.75% | 45.41% | 23.89% | 5.97% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-12; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -62.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NERV
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$10.6M | -$16.7M | -$2.8M | -$3.4M | -$3.9M | -$4.4M | -$6.3M | -$6.7M |
| Net income | $17.5M | -$125.4M | -$2.7M | -$3.3M | -$3.8M | $22.5M | -$8.2M | -$8.6M |
| EPS (diluted) | $-0.14 | $-2.86 | $-0.36 | $-0.43 | $-0.50 | $2.97 | $-1.09 | $-1.13 |
| EPS (basic) | $0.36 | $-2.86 | $-0.36 | $-0.43 | $-0.50 | $2.97 | $-1.09 | $-1.13 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $95.1M | $94.0M | $98.0M | $28.1M | $30.4M | $32.8M | $37.1M | $42.8M |
| Total liabilities | $296.6M | $343.1M | $233.8M | $62.7M | $62.5M | $61.9M | $62.8M | $64.5M |
| Stockholders' equity | -$213.3M | -$254.0M | -$140.7M | -$34.6M | -$32.1M | -$29.1M | -$25.7M | -$21.7M |
| Total current assets | $79.7M | $79.1M | $83.1M | $13.0M | $15.5M | $17.9M | $22.3M | $27.9M |
| Total current liabilities | $4.0M | $4.5M | $2.3M | $2.7M | $2.5M | $1.9M | $2.8M | $4.5M |
| Cash & equivalents | $24.7M | $32.7M | $82.3M | $12.3M | $15.2M | $17.3M | $21.4M | $26.5M |
| Marketable securities (current) | $50.6M | $45.4M | — | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | $0 | $1.4K | $2.7K | $4.1K | $5.4K | $6.8K |
| Goodwill | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.4M | $2.1M | $639.7K | $944.5K | $896.8K | $639.9K | $1.6M | $553.2K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.7K | $4.4K | $4.3K | $699 | $699 | $699 | $699 | $699 |
| Retained earnings | -$796.7M | -$814.2M | -$688.8M | -$405.1M | -$402.4M | -$399.1M | -$395.4M | -$391.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.3M | -$5.4M | -$4.5M | -$2.9M | -$2.0M | -$4.1M | -$5.2M | -$4.4M |
| Investing cash flow | -$4.8M | -$45.3M | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $10.2M | $1.1M | $74.5M | -$45.2K | $0 | $0 | — | — |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $2.3M | $8.7M | $459.0K | $272.9K | $298.2K | $297.2K | $249.7K | $307.7K |
| Change in accounts payable | -$693.7K | $1.5M | -$275.2K | -$72.7K | $256.9K | -$967.9K | $1.1M | -$275.2K |
| Purchases of investments | $9.8M | $45.3M | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M |
| EPS (diluted) | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 |
| EPS (basic) | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
| Stockholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M |
| Total current assets | $83.1M | $22.3M | $42.0M | $40.2M | $62.2M |
| Total current liabilities | $2.3M | $2.8M | $3.3M | $1.4M | $2.8M |
| Cash & equivalents | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M |
| Marketable securities (current) | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $0 | $5.4K | $10.9K | $16.3K | — |
| Goodwill | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $639.7K | $1.6M | $1.8M | $969.7K | $1.9M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $4.3K | $699 | $699 | $534 | $534 |
| Retained earnings | -$688.8M | -$395.4M | -$396.8M | -$366.8M | -$334.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Investing cash flow | $0 | $0 | $0 | -$16.3K | — |
| Financing cash flow | $74.5M | — | $19.6M | -$5 | $60.0M |
| Free cash flow | — | — | — | -$24.7M | — |
| Capital expenditures | — | — | — | $16.3K | — |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $1.3M | $1.3M | $2.0M | $4.1M | $5.2M |
| Change in accounts payable | -$1.1M | -$197.5K | $835.7K | -$883.5K | $857.6K |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NERV as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-23 08:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-12 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
Recent news
Headlines about NERV (Minerva Neurosciences, Inc). Links open the publisher — we don’t host full articles.
-
NERV Nov 2026 2.500 call (NERV261120C00002500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-22 -
Minerva (NERV) Advances +9.05% as Buying Pressure Builds 2026-10-21 - TWAP Entry
www.dars.gov.et · 2026-10-21 -
Minerva Neurosciences, Inc. (NERV) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
Yahoo Finance · 2026-08-28 -
Minerva Neurosciences GAAP EPS of -$0.14 beats by $0.06
Seeking Alpha · 2026-08-07 -
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Yahoo Finance · 2026-08-07 -
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Yahoo Finance · 2026-06-01 -
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Yahoo Finance · 2026-05-20
No headlines in this category right now — try “All”.